Literature DB >> 15492987

Expression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1 [Flt-1] and VEGF-R2 [KDR/Flk-1]) in tumorlets and in neuroendocrine cell hyperplasia of the lung.

Hervé Sartelet1, Myriam Decaussin, Gilles Devouassoux, Béatrice Nawrocki-Raby, Pierre-Yves Brichon, Christian Brambilla, Elisabeth Brambilla.   

Abstract

Pulmonary tumorlets and neuroendocrine (NE) cell hyperplasia are part of a continuous spectrum of NE-cell hyperplasia, going from NE hyperplasia to carcinoid. Vascular endothelial growth factor (VEGF) is a potent endothelial cell mitogen that has been shown to be increased in hypoxic lung. We hypothesized that tumorlets and NE-cell hyperplasia, which occur frequently in this context, were partly responsible for VEGF secretion. Immunohistochemical analysis of VEGF and both VEGF-R1 and VEGF-R2 was performed on paraffin sections of 12 lung tissues containing tumorlets and NE-cell hyperplasia in parallel with a control group of 11 lung specimens. VEGF and its receptor expressions were compared in bronchial epithelial cells and endothelial cells in both groups. VEGF and its receptors were consistently expressed in tumorlets and in NE-cell hyperplasia. When compared with control group lungs, the staining score for VEGF in lung bearing tumorlets was significantly higher in endothelial cells, but was not different in bronchial epithelial cells. VEGF-R1 expression was significantly increased both on bronchial epithelial cells (P = 0.001) and endothelial cells (P = 0.006), and VEGF-R2 expression was significantly increased on endothelial cell (P = 0.044). There was a significant positive correlation between the level of expression of VEGF and VEGF-R1 (P = 0.04) in both control groups and lung bearing tumorlets, but there was no significant correlation between VEGF and VEGF-R2 expression (P = 0.1). We concluded that VEGF is highly expressed in localized NE cell proliferations without potential of malignancy and might participate in local development of fibrosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15492987     DOI: 10.1016/j.humpath.2004.07.009

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

Review 1.  Cholangiocyte proliferation and liver fibrosis.

Authors:  Shannon S Glaser; Eugenio Gaudio; Tim Miller; Domenico Alvaro; Gianfranco Alpini
Journal:  Expert Rev Mol Med       Date:  2009-02-25       Impact factor: 5.600

2.  Taurocholate feeding to bile duct ligated rats prevents caffeic acid-induced bile duct damage by changes in cholangiocyte VEGF expression.

Authors:  Romina Mancinelli; Paolo Onori; Eugenio Gaudio; Antonio Franchitto; Guido Carpino; Yoshiyuki Ueno; Domenico Alvaro; Luigi P Annarale; Sharon Demorrow; Heather Francis
Journal:  Exp Biol Med (Maywood)       Date:  2009-02-20

3.  Pulmonary carcinoid tumorlet without underlying lung disease: analysis of its relationship to fibrosis.

Authors:  Ping He; Xia Gu; Qinian Wu; Yunen Lin; Yingying Gu; Jianxing He
Journal:  J Thorac Dis       Date:  2012-12       Impact factor: 2.895

4.  Neuroendocrine tumors of the lung.

Authors:  Annette Fisseler-Eckhoff; Melanie Demes
Journal:  Cancers (Basel)       Date:  2012-07-31       Impact factor: 6.639

5.  Tyrosine phosphorylation modulates the vascular responses of mesenteric arteries from human colorectal tumors.

Authors:  Eduardo Ferrero; María Dolores Mauricio; Miriam Granado; Oscar García-Villar; Martín Aldasoro; José María Vila; Manuel Hidalgo; Jorge Luis Ferrero; Nuria Fernández; Luis Monge; Angel Luis García-Villalón
Journal:  Biomed Res Int       Date:  2013-11-10       Impact factor: 3.411

6.  A case of lung tumorlets secondary to pulmonary hypoplasia with recurrent haemoptysis.

Authors:  Kyoko Yagyu; Atsushi Miyamoto; Haruhiko Matsushita; Akira Okimora
Journal:  Respirol Case Rep       Date:  2018-09-28

7.  Carcinoid Tumorlets Co-Existing with Chronic Pulmonary Inflammatory Processes: Imaging Findings and Histological Appearances.

Authors:  Jun Wang; Shuai Ren; Yongkang Liu; Kai Guo; Xiao Chen; Zhongqiu Wang; Rong Chen
Journal:  Med Sci Monit       Date:  2020-09-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.